99mTc-exendin(9-39)/octreotide: biokinetics and radiation dosimetry in healthy individuals
Conclusion: All the absorbed doses were comparable to those known for most of the 99mTc studies. 99mTc-exendin(9-39)/octreotide obtained from kit formulations showed high tumor uptake in a patient with a malignant lesion, making it a promising imaging radiopharmaceutical to target GLP-1R and SSTR.
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: Original Articles Source Type: research
More News: Cancer & Oncology | Cardiology | CT Scan | Heart | Liver | Nuclear Medicine | SPECT | Study | Urology & Nephrology